Chr. Hansen

FY 2020/21 Results

October 14, 2021

1

Safe harbor statement

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words "believe," "expect," "anticipate," "intend," "estimate," "outlook," "will," "may," "continue," "should" and similar expressions identify forward-looking statements.

Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company's markets; the impact of regulatory initiatives; and the strength of competitors. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in records and other data available from third parties.

Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and may be beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements.

The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward- looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations.

By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions.

2

A transition year with increased complexity from portfolio changes & COVID-19

Financial highlights Q4/FY 2020/21

ORGANIC GROWTH

EBIT MARGIN

FREE CASH FLOW

before special items

before acquisitions,

special items and divestment

6%

28.8% reported

EUR 77m

Q4 2020/21

32.6% underlying1

Q4 2019/20: 9%

Q4 2019/20: EUR 81m

Q4 2019/20: 38.4% (38.2% underlying)

7%

27.7% reported

EUR 196m

FY 2020/21

FY 2019/20: 6%

31.4% underlying1

FY 2019/20: EUR 225m

FY 2019/20: 33.7% (33.6% underlying)

1 Underlying EBIT margin b.s.i. excludes recent acquisitions. See Q4 2020/21 company announcement, p. 22 for reconciliation.

3

Good progress on innovation pipeline and lighthouses

Strategic highlights Q4/FY 2020/21 - REINVEST and LEVERAGE

REINVEST IN CORE TO DEFEND AND STRENGTHEN MARKET POSITION

  • All-timehigh launch activity in Dairy

Animal Health registered 50+ new products and launched new cattle probiotic BOVACILLUS™ and first probiotic range for pet food

  • Good progress on scientific marketing initiatives in Human Health e.g. The Probiotic Institute

LEVERAGE MICROBIAL PLATFORM TO GROW LIGHTHOUSES

AND EXPAND INTO NEW AREAS

  • Bioprotection launched 3rd generation FRESHQ® for fermentation-enabled bioprotection

Fermented Plant Bases introduced VEGA™ brand and new cultures

  • Plant Health diversified portfolio with the launch of ACCUDO® and the expansion into Canada; partnership with UPL announced
  • Bacthera received manufacturing licenses for clinical trial production

Integration of acquisitions largely completed

Strategic highlights Q4/FY 2020/21 - EXTEND

UAS LABS/ HSO HEALTH CARE

Diversified Human Health customer base

  • Less dependency on key accounts and larger exposure to e-commerce

Expanded probiotic product and strain offering

  • Expansion of SCIENCE range with documented premium strains and acquisition of a POWERED range for multi- strain segment

Strengthened manufacturing capabilities for solution selling

  • Increased production flexibility with additional fermentation capacity in US
  • Better control of full value chain through in-house finished product capabilities

JENNEWEIN

Expansion of microbial and fermentation technology platforms

  • HMO are produced via fermentation and adjacent to probiotics
  • Synergies from combined R&D and commercial capabilities

Shape an emerging high-growth market as a first mover

  • Jennewein is one of the early pioneers with strong IP
  • Growth will be driven by premiumization and demand for 'close-to-nature' infant formula products
  • Huge potential of EUR >1bn long-term but market is delayed due to registration delays and longer timelines

Attachments

  • Original document
  • Permalink

Disclaimer

Chr. Hansen Holding A/S published this content on 14 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 October 2021 07:31:04 UTC.